zoom UAE’s port developer and operator Abu Dhabi Ports has signed a Memorandum of Understanding (MoU) with the Italian Export Credit company (SACE) at the UAE pavilion of ‘Expo Milan 2015’.SACE facilitates access to credit lines to support companies and banks in their internationalisation process, in addition to its traditional business of export credit and investment protection.The MoU aims to formalise a common base for the purpose of exploring, strengthening and enhancing the trade and economic cooperation between UAE and Italy, through the exchange of information and business opportunities.“Khalifa Industrial Zone Abu Dhabi (Kizad), the industrial and logistics hub integrated with our flagship Khalifa Port has tailored offerings for Italian companies looking to expand their business into Abu Dhabi and the region. Our world-class business environment, state-of-the-art facilities and infrastructure, as well as dedicated investor support has already attracted a good deal of foreign direct investments, including Italian businesses,” said Captain Mohamed Juma Al Shamisi, CEO of Abu Dhabi Ports.“Khalifa Port is an expression of the economic and industrial diversification strategy of the Emirate of Abu Dhabi, to which Italian companies can contribute with their know-how in key sectors for the Emirate economy,” said Alessandro Castellano, CEO of SACE.“The agreement signed today with Abu Dhabi Ports opens important new growth opportunities for Made in Italy in the UAE, where our companies export € 5 billion in goods and services.”Italy is the UAE’s second largest trade partner in Europe. The bilateral trade stood at about Dh30 billion in 2014, which represented more than half of Italy’s trade with GCC countries. A total of 118 Italian companies, 478 commercial agencies and 7,452 brands have registered with the UAE Ministry of Economy until the end of 2014.
Developing nations need better access to information that can improve the safety and quality of their medicines, the United Nations World Health Organization (WHO) said today.“Lower-income countries must be allowed to benefit from the sophisticated monitoring systems that already exist in industrialized nations,” said WHO’s Executive Director for Health Technology and Pharmaceuticals, Anarfi Asamoa-Baah. “This can only be done through a truly multilateral system.” While it is difficult to estimate the number of casualties in developing countries caused by adverse drug reactions, WHO pointed out that there is a growing amount of substandard or counterfeit medicines on the market. And even in countries with good regulations and safety measures, adverse drug reactions occur frequently, like in the United States, where in 1998 negative effects from medicines were estimated to be between the fourth and sixth largest cause of death. WHO will make its case for greater global attention to the problem at a meeting the agency is organizing this week in Amsterdam. More than 50 countries will participate in the gathering, together with independent pharmacology experts, drug regulatory authorities and international professional organizations.